Pharmaids Pharmaceuticals (524572) Q2 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were approved by the Board on November 11, 2025.

• Statutory auditors issued an unmodified limited review report for both standalone and consolidated results.

Financial highlights

• Standalone revenue from operations for H1 FY26 was ₹596.55 lakhs, up from ₹100.05 lakhs in H1 FY25; consolidated revenue was ₹860.50 lakhs, up from ₹997.00 lakhs in H1 FY25.

• Standalone net loss for H1 FY26 was ₹165.23 lakhs, compared to a net loss of ₹263.00 lakhs in H1 FY25; consolidated net loss was ₹252.83 lakhs, compared to ₹568.76 lakhs in H1 FY25.

• Standalone EPS for H1 FY26 was ₹(0.47) vs. ₹(0.75) in H1 FY25; consolidated EPS was ₹(0.70) vs. ₹(1.61) in H1 FY25.

• Exceptional income of ₹313.05 lakhs recognized in standalone and ₹298.78 lakhs in consolidated results for H1 FY26.

Outlook and guidance

• The company continues to focus on its core segment of Contract Research and Manufacturing Services.